← MyLongPath

Pemgarda (pemivibart)

MedicationOff-label2 reviews
-2.5
Average score out of 5
Based on 2 experience(s)

Long-acting monoclonal antibody (pemivibart) authorized in the US for pre-exposure prophylaxis of COVID-19 in immunocompromised individuals. Sometimes discussed in Long COVID to reduce reinfection risk in vulnerable patients.

Brand names
Pemgarda
Information
Subcategory
monoclonal antibody
Evidence level
2/5
Evidence type
immunobridging study (FDA EUA)
Score distribution
+5
0 (0%)
+3
0 (0%)
+1
0 (0%)
0
1 (50%)
Negative
1 (50%)
Practical information
Time to effect
1-2 months
Reported side effects
Swelling (50%)worse POTS symptoms (50%)BP plummeted (50%)seemed to have allergic reaction/ over activated immune system (50%)
Latest reviews
F
Anonymous review0
26-35 y.o. · 4/25/2026

Immediate allergic like MCAS reaction treated with a shot of 60mg Prednisone and quick taper. The same symptoms slowly came back over the next month or so. Only combated with prednisone now at 62mg daily and trying to get off it.

F
Anonymous review-5
65+ · 4/21/2026

Had 3 infusions. No effect for #1 or #2. #3: immediate PEM, continuous flu like symptoms, nausea, severe fatigue. persisted x 1 month.

Share your experience

Your feedback helps thousands of people find what really works.

Join the community